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Background: Xenotransplantation using pig cells, tissues and organs may help to overcome the shortage of
human tissues and organs for the treatment of tissue and organ failure. Progress in the prevention of
immunological rejection using genetically modified pigs and new, more effective, immunosuppression regimens
will allow clinical application of xenotransplantation in near future. However, xenotransplantation may be associated
with the transmission of potentially zoonotic porcine microorganisms. Until now the only xenotransplantation-
associated transmission was the transmission of the porcine cytomegalovirus (PCMV) into non-human primates.
PCMV caused a significant reduction of the survival time of the pig transplant.
Main body of the abstract: Here the available publications were analysed in order to establish the mechanism
how PCMV shortened the survival time of xenotransplants. PCMV is a herpesvirus related to the human
cytomegalovirus and the human herpesviruses 6 and 7. These three human herpesviruses can cause serious disease
among immunocompromised human individuals, including transplant recipients. It was shown that PCMV
predominantly contributes to the reduction of transplant survival in non-human primates by disruption of the
coagulation system and by suppression and exhaustion of the immune system.
Conclusion: Although it is still unknown whether PCMV infects primate cells including human cells, indirect
mechanism of the virus infection may cause reduction of the xenotransplant survival in future clinical trials and
therefore PCMV has to be eliminated from donor pigs.
Keywords: Porcine cytomegalovirus, Xenotransplantation, Herpesviruses
Background
In the last years, a significant progress was achieved in the
development of xenotransplantation [1–4]. The main
achievements were the generation of pigs with multiple
genetic modifications [5–7] and new, more efficient
immunosuppression regimens [8, 9], allowing to overcome
the hyperacute rejection as well as other immunological
reactions. Increased survival times of different pig
transplants in non-human primates demonstrated the im-
pressive progress made in the field (Table 1) [3, 8–17].
However, immunological rejection and physiological
incompatibility are only two hurdles on the way to the
clinical application of xenotransplantation. Another hurdle
is the risk to transmit porcine microorganisms to the recipi-
ent which may induce severe disease (zoonosis or xenosis).
Microorganisms include bacteria, protozoa, fungi and vi-
ruses. In this context viruses are certainly the most harmful
microorganisms due to the lack of effective antivirals and
vaccines. Among the porcine viruses of interest are DNA
viruses such as PCMV, the porcine circoviruses 1, 2 and 3
(PCV1, PCV2, PCV3), and the porcine lymphotropic
herpesviruses (PLHV-1, PLHV-2, PLHV-3) as well as RNA
viruses such as the hepatitis E virus (HEV), the porcine
reproductive and respiratory syndrome virus (PRRSV) and
the Nipah virus (NIV) (for reviews discussing each virus
type in the context of xenotransplantation see [18–25]).
Some of these viruses, e.g. PCV2, PRRSV and NIV, cause
severe disease in the infected pigs and can easily be
detected. For the detection of the viruses not causing
diseases in the infected pigs sensitive screening methods
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are required. Among the viruses with potential zoonotic
potential are also the porcine endogenous retroviruses
(PERVs) which are integrated in the genome of all pigs and
which - in contrast to all other porcine viruses, bacteria
and fungi - cannot be eliminated by selection of negative
animals, vaccination, treatment, early weaning, colostrum
deprivation, Caesarean delivery or embryo transfer [26].
This manuscript will concentrate on the mechanism how
PCMV contributes to the reduction of transplant survival.
Main text
Risk evaluation of some porcine viruses
Viruses affecting the health of the donor pigs will harm the
transplant and have to be eliminated. For some of these vi-
ruses effective vaccines exist, which prevent the infection or
at least the outbreak of the disease. More difficult is the
situation with viruses not affecting the health of the donor
pigs. With two exceptions we do not know whether trans-
mission of these viruses will harm the transplant recipient.
On exception is HEV. It was shown that HEV can be trans-
mitted to humans by undercooked meat or contact and
that infection of immune-compromised humans leads to a
chronic HEV infection, whereas infection of individuals
with pre-existing liver disease may be fatal [20, 21]. There
are no licensed vaccines or effective antivirals against HEV.
The other, more important exception, is PCMV, which will
be discussed in the next chapter.
The risk posed by PERV is difficult to evaluate. Retrovi-
ruses are known to induce tumours and / or immunodefi-
ciency in the infected individuals. Until now, no transmission
of PERV was observed in numerous pig to non-human pri-
mate xenotransplantations and in first clinical trials in
humans [26, 27]. If recent reports, demonstrating inactiva-
tion of all PERVs in pig cells [28] and in live animals [29] by
gene editing using clustered regularly interspaced short pal-
indromic repeats/ CRISPR associated (CRISPR/Cas), can be
confirmed, the risk posed by PERV will be eliminated [30].
Special case: PCMV
PCMV is an enveloped DNA virus belonging to the fam-
ily Herpesviridae, subfamily Betaherpesvirinae, genus
Roseolovirus [31]. PCMV is found in the tissues through-
out the body including the nose of infected newborn
piglets where it causes rhinitis and conjunctivitis. Most
infections are sub-clinical, clinical disease is rare [32].
Clinical signs are only seen if PCMV infects a sow for
the first time when she is late in pregnancy. Foetal
deaths, mummified foetuses, stillbirths, and weak piglets
are observed. The virus is shed in discharges from the
nose and eyes, urine and farrowing fluids, it is also
transmitted via the boar through semen and crosses the
placenta to infect piglets before birth [32–34].
Despite the similar name, PCMV is more closely related
with human herpesvirus-6 (HHV-6) and HHV-7, which
are also Roseoloviruses, but not so closely with the human
cytomegalovirus (HCMV), also called HHV-5 [31, 35, 36].
HCMV is the cause of disease in the human fetus, the
allograft recipient, AIDS patient, those admitted to inten-
sive care units, and in the elderly [37]. HCMV is the single
most important infectious agent affecting recipients of
organ transplants, with at least two-thirds of these pa-
tients having CMV infection after transplantation [38].
During solid organ transplantation, seropositive donors
frequently transmit HCMV to seronegative recipients (pri-
mary infection) [38, 39]. Primary infection has the greatest
clinical impact. In addition, during allotransplantation
HCMV may be re-activated by the allo-immune responses
and by the immunosuppression in the HCMV-positive re-
cipient [40]. Finally, superinfections have been described
[38]. Pneumonia induced by HCMV is most common
after lung and heart/lung transplantations in humans
[41, 42], however, the spectrum of CMV pneumonia has
changed with the introduction of routine antiviral prophy-
laxis [43–45]. Consumptive coagulopathy (CC) and
thrombotic microangiopathy have been described in dis-
seminated HCMV infection in humans [43, 44]. The
thrombotic microangiopathy can be treated by ganciclovir.
HCMV produces overt disease only if the viral load in-
creases to high levels. Due to a robust immune response
the infected individual usually remains asymptomatic.
However, this permanent control of HCMV impairs the
immune system and leads to immunosuppression [37].
HCMV carry in its genome the viral gene UL111A, which
encodes a viral IL-10 which is homoloque to the cellular
IL-10, a well-known immunosuppressive cytokine [45].
This protein is also expressed in healthy HCMV-positive
donors and may play a key role in sensing or modifying
the host environment during latency [46].
As mentioned, the human roseoloviruses HHV-6A,
HHV-6B and HHV-7 are more closely related with
PCMV, even cross-reacting antibodies have been ob-
served in humans [47]. HHV-6A, HHV-6B and HHV-7
Table 1 Survival time of different porcine xenotransplants in
non-human primates
Pig transplant Longest survival
time (days)
Reference
Islet cells 950 Shin et al., [10]
Hearts, heterotopic 945 Mohiuddin et al., [8]
Hearts, orthotopic 57 Byrne et al., [11]
Kidney 499 Higginbotham et al., [9],
Iwase et al., [12, 13],
Wang et al., [3],
Kim et al., [17]
Neurones 549 Badin et al., [14]
Cornea 511 Kim et al., [15]
Liver 29 Wang et al., [3]
Lung 10 Watanabe et al., [16]
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are widely distributed in the human population. Like
other herpesviruses, these viruses cause acute infection,
establish latency, and in the case of HHV-6A and
HHV-6B, whole virus can integrate into the host
chromosome [48]. Primary infection with HHV-6B oc-
curs in nearly all children and was first linked to the
clinical syndrome roseola infantum. However, roseolo-
virus infection results in a spectrum of clinical disease,
ranging from asymptomatic infection to acute febrile ill-
nesses with severe neurologic complications. Generally,
reactivation of roseoloviruses has been associated with
various clinical syndromes including fever, encephalitis,
pneumonitis, hepatitis, bone marrow suppression, and a
graft versus host disease (GVHD)-like rash, however
co-infection with other viruses including HCMV cannot
be excluded [49]. HHV-6 and HHV-7 are together with
HCMV common infections in transplant recipients and
have been clearly associated with early transplant rejec-
tion [38, 50–53].
Reduction of transplant survival time in non-human
primates by PCMV
PCMV is the first virus with proven pathogenicity in
xenotransplantation. In numerous preclinical trials
transplanting pig organs into non-human primates, a
significant reduction of the survival time was observed
(Table 2) [54–60]. Transplantation of PCMV-positive
thymokidneys into baboons resulted in an increased
PCMV titre, hematuria, systemic coagulopathy and a re-
duced survival time of the pig xenotransplant [54].
Transplanting pig kidneys into baboons, the first kid-
ney coming from a PCMV-positive animal failed after 13
days and a second kidney from a PCMV-negative animal
was transplanted after excision of the first kidney. The
second transplant survived for 60 days without
hemorrhagic changes, clearly demonstrating the PCMV
infection was the reason of the short survival time of the
first transplant [58].
Transmission of PCMV was also observed in orthoto-
pic pig heart transplantations in baboons [61, 62].
PCMV-positive cells were found disseminated in the ba-
boon recipient, it seemed likely that these are
PCMV-infected pig cells [63]. The influence on the sur-
vival time in this setting is still unclear. In this case, rep-
lication in the xenotransplant, the pig heart, should be
sufficient to generate a high virus load in the blood of
the baboon.
Are herpesviruses species-specific?
At present it is still unclear, whether PCMV can infect
human and non-human primate cells. There is one re-
port showing infection of human cells [64] and another
not showing infection [65]. Ever since their first isola-
tion, cytomegaloviruses have been recognized as being
highly species specific, replicating only in cells of their
own or a closely related host species, while cells of
phylogenetically more distant hosts are usually not per-
missive for viral replication. For instance, HCMV repli-
cates in human and chimpanzee fibroblasts but not in
rodent cells, and murine cytomegalovirus (MCMV) rep-
licates in cells of mice and rats but not in primate cells
[66]. However, MCMV can be adapted stepwise to mu-
tate and replicate in cultured human cells [66]. Because
a single gene of the HCMV encoding a mitochondrial
inhibitor of apoptosis is sufficient to allow MCMV repli-
cation in human cells, induction of apoptosis was
thought to serve as an innate immune defence to inhibit
cross-species infections of rodent CMVs [67]. MCMV is
also thought to be a species-specific virus, however a re-
combinant MCMV entered and expressed reporter genes
in both rat and human brain cells [68]. These data show
that under certain conditions cytomegaloviruses may
mutate and replicate in other species. In the case of the
mutated MCMV able to replicate in human cells only a
limited number of mutations was detected [66]. When
analysing PCMV in baboons which received a
PCMV-infected pig heart, low numbers of
PCMV-positive cells were found in all organs of the ba-
boon, suggesting that disseminated pig cells produce the
virus found in the blood [63].
Another example for transspecies transmission of a
herpesvirus is the baboon cytomegalovirus (BaCMV).
This virus was shown to infect human cell in vitro [69].
Furthermore, BaCMV was found in a human recipient
after transplantation of a baboon liver and BaCMV able
to replicate on human cells was isolated from the patient
[70]. Meanwhile it was also shown that HCMV infects
pig cells [71].
Possible mechanisms how PCMV causes reduction of the
transplant survival time
Since several reviews concerning the role of PCMV in
xenotransplantation have been published [18, 19, 22, 72],
here mainly the mechanisms leading to a reduced sur-
vival will be put into focus and analysed in more details
(see Table 2). There are two main mechanisms: First, the
influence on the coagulation system, and, second, the in-
fluence on the immune system of the infected animal.
Consumptive coagulopathy (CC) defined by
thrombocytopenia, decreasing fibrinogen, and haemor-
rhage, has been observed in pig to non-human primate
xenotransplantations [73–75]. Infections with other her-
pesviruses have also been shown to directly activate pro-
thrombin and initiate clotting [76, 77]. In vitro
activation of the porcine tissue factor (TF) by PCMV in-
fection of porcine aortic endothelial cells (PAEC) was re-
ported, although in vivo no correlation between TF
activation and PCMV infection was observed [55]. When
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pig kidneys were transplanted into baboons, an en-
hanced intercellular adhesion molecule 1 (ICAM-1) ex-
pression was observed in the transplant (endothelial cell
activation) [58]. This reminds the situation with HCMV.
After in vitro infection of HUVEC (human umbilical
vein endothelial cells) with HCMV also an enhanced
ICAM-1 expression was observed [78].
PCMV is an immunosuppressive virus modulating the
expression of immune-related genes [79]. A PCMV infec-
tion in pigs is often associated with opportunistic bacterial
infections [35]. Transcriptome analysis of PCMV-infected
thymuses showed that numerous immune-regulatory genes
were up- or downregulated [80]. When porcine micro-
RNAs (miRNA) were analysed in PCMV-infected and
none-infected porcine macrophages, the differentially
expressed miRNA were mainly involved in immune and
metabolic processes [81].
PCMV and PERVs
No increased expression of PERV in transplanted pig kid-
neys from PCMV-positive animals compared with kidneys
from uninfected animals was reported [82]. The interaction
of PCMV and PERV deserves further investigation, espe-
cially in lymphoid tissues. So it was shown that allogenic
stimulation [83] or cultivation in culture medium [63] of
pig PBMCs significantly enhanced the expression of
PCMV. On the other hand, stimulation of pig PBMCs with
mitogens induced an enhanced expression of PERV associ-
ated with release of virus particles [84–86]. In this context
two scenarios are of interest and should be investigated:
PERV-expression in PCMV-infected pig immune cells and
PERV-expression in pig lymphocytes immune-stimulated
by PCMV.
How to prevent PCMV transmission
Like many of the potentially zoonotic microorganisms,
PCMV can be eliminated by selection of PCMV-negative an-
imals or by early weaning. Since PCMV can be transmitted
via the placenta, Caesarean section, colostrum deprivation
and embryo transfer may be useful. There were some efforts
to eliminate PCMV by early weaning [57, 87]. Only recently
it was shown that early weaning completely eliminated por-
cine cytomegalovirus from a newly established facility for pig
donors generated for xenotransplantation [88].
Antiviral drugs such as ganciclovir, cidofovir and to a
lesser extent the more toxic compounds foscarnet and
acyclovir have been shown to inhibit replication of
PCMV [89]. However, PCMV – in contrast to the hu-
man CMV – is highly resistant to ganciclovir [90]. Un-
fortunately, vaccines against PCMV are not yet available,
although first immunisation experiments with PCMV-
derived antigens were successful [91].
Conclusion
PCMV is the first virus with proven pathogenicity in xeno-
tranplantation. In numerous preclinical trials transplanting
pig organs into non-human primates, a significant
reduction of the survival time was observed when the
organs were PCMV-infected. The possible mechanisms of
reduction of survival time are based on the disruption of
the coagulation system and by suppression and exhaustion
of the immune system. Although PCMV is resistant against
antivirals which are effective against other herpesviruses
and although vaccines against PCMV do not exist, PCMV
can easily eliminated by early weaning and isolation of the
negative animals.
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